目的:观察桂枝肌瘤丸治疗慢性盆腔炎的临床疗效。方法:江苏盛泽医院自愿参与本次研究的100例慢性盆腔炎(血瘀证)患者,采用随机数字表法分为观察组和对照组各50例,两组患者均采用常规西医疗法,观察组在对照组的基础上加用桂枝肌瘤丸,两组患者均连续治疗3个月后观察临床疗效。结果:治疗后观察组患者全血低、高切粘度及血浆粘度、红细胞聚集指数、血沉均显著低于对照组(P<0.05),下腹部胀痛刺痛、腰骶部胀痛、经期腹痛加重、月经不调、乳房胀痛、带下异常、低热等症状评分均显著低于对照组(P<0.05),CD4+、CD4+/CD8+显著高于对照组(P<0.05),CD8+显著低于对照组(P<0.05),盆腔包块显著小于对照组(P<0.05),临床愈显率(82.00%)显著高于对照组(64.00%)(P<0.05)。两组患者总有效率差异无统计学意义(P>0.05)。结论:桂枝肌瘤丸结合西医疗法治疗慢性盆腔炎在改善患者血液流变学、中医症状积分、缩小盆腔包块及改善患者细胞免疫方面具有更好的疗效。 Objective: To observe the clinical effect of Gui Zhi Mi tumor pills in treating chronic pelvic inflammatory disease. Methods: One hundred patients with chronic pelvic inflammatory disease (blood stasis syndrome) who participated voluntarily in this study in Jiangsu Shengze Hospital were divided into observation group (50 cases) and control group (50 cases) by random number table. Both groups were treated by conventional western medicine Group in the control group based on the use of Gui Zhi Mi tumor pills, two groups of patients were treated for 3 months after treatment to observe the clinical efficacy. Results: After treatment, the low blood pressure, high shear viscosity, plasma viscosity, erythrocyte aggregation index and erythrocyte sedimentation rate in the observation group were significantly lower than those in the control group (P <0.05), lower abdominal pain and pain, lumbosacral pain, menstrual abdominal pain (P <0.05), CD4 +, CD4 + / CD8 + were significantly higher than those in control group (P <0.05), CD8 + was significantly lower than that of control group The pelvic mass in the control group was significantly lower than that in the control group (P <0.05), and the clinical cure rate (82.00%) was significantly higher than that in the control group (64.00%) (P <0.05). There was no significant difference in the total effective rate between the two groups (P> 0.05). Conclusion: Guizhi Fiboma combined with western medicine treatment of chronic pelvic inflammatory disease in patients with improved hemorheology, symptom scores, reduce pelvic mass and improve cellular immune cells in patients with better efficacy.